Abbott Laboratories (NYSE:ABT) Stock Holdings Increased by DORCHESTER WEALTH MANAGEMENT Co

DORCHESTER WEALTH MANAGEMENT Co lifted its stake in Abbott Laboratories (NYSE:ABTFree Report) by 36.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,708 shares of the healthcare product maker’s stock after purchasing an additional 1,521 shares during the quarter. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Abbott Laboratories were worth $628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Halpern Financial Inc. acquired a new position in Abbott Laboratories during the third quarter valued at approximately $26,000. Altshuler Shaham Ltd bought a new position in Abbott Laboratories in the fourth quarter worth $28,000. Cornerstone Planning Group LLC bought a new position in Abbott Laboratories in the second quarter worth $28,000. CGC Financial Services LLC bought a new position in Abbott Laboratories in the second quarter worth $32,000. Finally, FWL Investment Management LLC bought a new position in Abbott Laboratories in the fourth quarter worth $33,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Andrea F. Wainer sold 42,500 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now owns 65,027 shares in the company, valued at approximately $7,315,537.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,435 shares of company stock worth $6,451,298. Corporate insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Citigroup raised their target price on Abbott Laboratories from $123.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Royal Bank of Canada reissued an “outperform” rating and set a $128.00 price objective on shares of Abbott Laboratories in a report on Wednesday, February 14th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b-” rating in a report on Thursday, December 21st. Barclays lifted their price target on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a report on Friday, January 26th. Finally, Wells Fargo & Company lifted their price target on Abbott Laboratories from $116.00 to $121.00 and gave the company an “overweight” rating in a report on Wednesday, December 13th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $121.77.

Check Out Our Latest Report on ABT

Abbott Laboratories Stock Down 0.1 %

Shares of ABT traded down $0.09 on Wednesday, hitting $111.93. The company’s stock had a trading volume of 706,109 shares, compared to its average volume of 5,620,528. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35. The firm’s fifty day moving average price is $115.02 and its 200-day moving average price is $106.74. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64. The firm has a market capitalization of $194.22 billion, a price-to-earnings ratio of 34.36, a P/E/G ratio of 2.70 and a beta of 0.74.

Abbott Laboratories (NYSE:ABTGet Free Report) last issued its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.19. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The business had revenue of $10.24 billion during the quarter, compared to analyst estimates of $10.19 billion. During the same period in the previous year, the firm earned $1.03 EPS. Abbott Laboratories’s quarterly revenue was up 1.5% compared to the same quarter last year. On average, equities research analysts expect that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 1.97%. The ex-dividend date is Friday, April 12th. Abbott Laboratories’s payout ratio is 67.48%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.